Organ transplant recipients are at a higher risk of pre-malignant human papillomavirus-associated lesions due to immunosuppression. The efficacy of immunomodulants such as imiquimod 5% is not yet fully evaluated in this population. We describe a case of vulval intra-epithelial neoplasia in a renal transplant recipient which was successfully treated with topical imiquimod.
BaandrupLVarboAMunkCet al.
In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978–2007 – a nationwide population-based study. Gynecol Oncol2011;
122: 45–49.
2.
BornsteinJBogliattoFHaefnerHKet al.
The 2015 international society for the study of vulvovaginal disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol2016;
127: 264–268.
3.
FaberMTSandFLAlbieriVet al.
Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer2017;
141: 1161–1169.
SauderDN.Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol2000;
43: S6–S11.
6.
PepasLKaushikSBryantAet al.
Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev2011;
4: CD007924.
7.
TristramAHurtCNMaddenTet al.
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3 VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol2014;
15: 1361–1368.
8.
van SetersMvan BeurdenMten KateFJWet al.
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med2008;
358: 1465–1473.
9.
WestermannCFischerACladA.Treatment of vulvar intraepithelial neoplasia with topical 5% imiquimod cream. Int J Gynaecol Obstet2013;
120: 266–270.
10.
Rowert-HuberJPatelMJForschnerTet al.
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol2007;
156: 8–12.
11.
BrownVLAtkinsCLGhaliLet al.
Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients – randomized, double-blind, placebo-controlled trial. Arch Dermatol2005;
141: 985–993.
12.
OwensMBridsonWSmithSet al.
Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns1998;
5: 151.
13.
Santos-JuanesJEsteveAMas-VidalAet al.
Acute renal failure caused by imiquimod 5% cream in a renal transplant patient: review of the literature on side effects of imiquimod. Dermatology2011;
222: 109–112.
14.
VidalDMatias-GuiuXAlomarA.Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol2004;
29: 518–525.
15.
StockflethEMeyerTBenninghoffBet al.
Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol2001;
144: 1050–1053.
16.
HarwoodCAPerrettCMBrownVLet al.
Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol2005;
152: 122–129.
17.
TobyMConwayKSethiGet al.
Usual vulval intraepithelial neoplasia in HIV-positive women – a case series. Int J STD AIDS2016;
27: 1253–1256.
18.
GayedSL.Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient. Int J STD AIDS2002;
13: 349–351.
19.
UlrichCBichelJEuvrardSet al.
Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol2007;
157: 25–31.
